| 1 |
34359777 | WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells. | 2021 Jul 31 |
6 |
| 2 |
29235570 | Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. | 2018 Feb 20 |
5 |
| 3 |
30045945 | Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. | 2018 Aug 6 |
1 |
| 4 |
26832796 | Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. | 2016 Mar |
2 |
| 5 |
26883108 | Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3. | 2016 Mar 22 |
2 |
| 6 |
27183917 | Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity. | 2016 May 31 |
1 |
| 7 |
27626308 | The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma. | 2016 Oct 25 |
5 |
| 8 |
27991505 | Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis. | 2016 Dec 19 |
7 |
| 9 |
25658463 | WIP1 phosphatase as a potential therapeutic target in neuroblastoma. | 2015 |
3 |